JP2011522835A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522835A5
JP2011522835A5 JP2011512705A JP2011512705A JP2011522835A5 JP 2011522835 A5 JP2011522835 A5 JP 2011522835A5 JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011522835 A5 JP2011522835 A5 JP 2011522835A5
Authority
JP
Japan
Prior art keywords
cells
suppressor
antibody
isolated
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/046464 external-priority patent/WO2009149382A2/en
Publication of JP2011522835A publication Critical patent/JP2011522835A/ja
Publication of JP2011522835A5 publication Critical patent/JP2011522835A5/ja
Pending legal-status Critical Current

Links

JP2011512705A 2008-06-06 2009-06-05 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く Pending JP2011522835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5964708P 2008-06-06 2008-06-06
US61/059,647 2008-06-06
PCT/US2009/046464 WO2009149382A2 (en) 2008-06-06 2009-06-05 Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells

Publications (2)

Publication Number Publication Date
JP2011522835A JP2011522835A (ja) 2011-08-04
JP2011522835A5 true JP2011522835A5 (https=) 2012-07-19

Family

ID=41398905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512705A Pending JP2011522835A (ja) 2008-06-06 2009-06-05 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く

Country Status (14)

Country Link
US (1) US20090304659A1 (https=)
EP (1) EP2297204A4 (https=)
JP (1) JP2011522835A (https=)
KR (1) KR20110025812A (https=)
CN (1) CN102112491A (https=)
AU (1) AU2009255999A1 (https=)
BR (1) BRPI0915582A2 (https=)
CA (1) CA2728772A1 (https=)
IL (1) IL209798A0 (https=)
MX (1) MX2010013265A (https=)
NZ (1) NZ590197A (https=)
TW (1) TW201000130A (https=)
WO (1) WO2009149382A2 (https=)
ZA (1) ZA201100061B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5825966B2 (ja) * 2011-10-11 2015-12-02 株式会社日本バイオセラピー研究所 Ｃｄ５６陽性ｔ細胞増強方法
US10092597B2 (en) 2014-01-14 2018-10-09 The University Of Hong Kong Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice
WO2018085897A1 (en) * 2016-11-14 2018-05-17 Murdoch Childrens Research Institute Transplant rejection assay
SG11202000073XA (en) * 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
US20220227887A1 (en) 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
CN116723857A (zh) * 2020-07-21 2023-09-08 苏州智核生物医药科技有限公司 Cd8结合多肽及其用途
CN112156110B (zh) * 2020-09-15 2022-10-14 上海交通大学医学院 Cd8+抑制性t细胞在免疫调节中的应用及诱导方法
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法
CN120826463A (zh) * 2023-03-31 2025-10-21 杭州启函生物科技有限公司 使用工程化细胞的癌症免疫疗法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178858A (en) * 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
CA1339840C (en) * 1988-12-16 1998-04-28 Kenneth Kortright Method and apparatus for screening cells or formed bodies with populations expressing selected characteristics
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
DE69132373T2 (de) * 1990-11-23 2001-03-29 Coulter Corp., Hialeah Verfahren und vorrichtung zur reihensichtung mikroskopischer zellen unter verwendung von lichtstreuenden techniken
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
ATE432339T1 (de) * 1996-04-05 2009-06-15 Univ South Alabama Verwendung von onkofötal-antigen spezifischen cd4,cd8 zytotoxischen, suppressor t-zellen und interleukin-10
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
US6803036B1 (en) * 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US20040022761A1 (en) * 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
CN100350040C (zh) * 2002-09-27 2007-11-21 生物E股份有限公司 细胞分离组合物和方法
US20050042217A1 (en) * 2003-03-19 2005-02-24 Yan Qi Specific inhibition of allorejection
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
CN101511384A (zh) * 2006-06-30 2009-08-19 贝勒研究院 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞

Similar Documents

Publication Publication Date Title
JP2011522835A5 (https=)
JP7267976B2 (ja) 末梢免疫機能を調節するための方法及び組成物
Wang et al. Regulatory innate lymphoid cells control innate intestinal inflammation
EP3626817B1 (en) Methods of preparing anti-human papillomavirus antigen t cells
Van Driessche et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial
Zeng et al. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance
AU2006249640B2 (en) Dendritic cell compositions and methods
Yang et al. Interleukin-35 dampens CD8+ T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma
TW200916581A (en) Paracrine signals from mesenchymal feeder cells and regulating expansion and differentiation of hepatic progenitors using same
Roberts et al. TNF blockade maintains an IL-10+ phenotype in human effector CD4+ and CD8+ T cells
de Haar et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation
CN101514333B (zh) 一种免疫耐受型树突状细胞及其制备方法与专用培养基
EP2857498A1 (en) Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same
LeÓn et al. Cytokine production by intestinal intraepithelial lymphocyte subsets in celiac disease
CN103589685B (zh) 一种dc细胞的快速制备方法
Kolanowski et al. Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ–matured type I dendritic cells for immunotherapy
Clanchy et al. The development of macrophages from human CD34+ haematopoietic stem cells in serum-free cultures is optimized by IL-3 and SCF
Gel’m et al. Functional activity of lymphocytes of healthy donors and cancer patients after culturing with IL-2 and IL-15
CN108251370A (zh) 非细胞来源的多肽致敏的dc-cik细胞、其构建方法及应用
Abediankenari et al. Comparison of several maturation inducing factors in dendritic cell differentiation
Li et al. The regulatory role of dendritic cells in the immune tolerance
CN113444688B (zh) 用于抗病毒抗肿瘤的人树突状细胞诱导方法及组合物
CN108486055A (zh) 培养基及其在中央记忆型t淋巴细胞培养中的应用
Hildenbrand et al. IFN-γ enhances Th1 polarisation of monocyte-derived dendritic cells matured with clinical-grade cytokines using serum-free conditions
CN105219727A (zh) 一种用于激活结直肠癌特异性免疫反应的试剂盒